While the exact etiology of rosacea remains to be elucidated,
it is now widely accepted that it is a chronic
inflammatory condition that occurs in the context
of an altered innate immune response.1 The current model for
rosacea suggests that environmental changes induced by microbes
(such as Demodex folliculorum), hormonal shifts, or UV
light exposure are detected by pattern recognition receptors
of the immune system. Subsequent signaling-induced effector
molecules, such as cytokines, cathelicidin, chemokines and reactive
oxygen species may then modify dermal structure through
vascular changes, lymphohistiocytic infiltration, neutrophil recruitment,
and collagen degradation, which may perpetuate
this response.2,3 Most current therapies are aimed at modulating
various points of this inflammatory cascade.
Systemic Therapy
Despite the fact that a clear bacterial pathogen has not been
implicated in the pathophysiology of rosacea , antibiotics have numerous
anti-inflammatory properties which include suppressing
neutrophil migration and chemotaxis, inhibiting angiogenesis,
blocking the production of matrix metalloproteinases (MMPs),
inhibiting the activation, proliferation and migration of lymphocytes
and upregulating anti-inflammatory cytokines.5,6
The most common systemic drugs include doxycycline, erythromycin,
minocycine, tetracycline, metronidazole, and occasional
off-label low-dose isotretinoin.7 Subantimicrobial low-dose oral
doxycycline has been shown to be effective with less risk of affecting
endogenous flora and lower chance of development of
antibiotic resistant strains.8
Topical Therapeutic Options
The most common topical medications include azelaic acid,
metronidazale, erythromycin, or sodium sulfacetamide 10% and
sulfur 5%.9 Recently, pimecrolimus 1% cream has been found
to be effective for mild to moderate inflammatory rosacea.10,11
Choice of vehicle (lotion, cream, gel foam) can influence tolerability
in patients who often have heightened skin sensitivity.
Many rosacea patients who perceive their skin as sensitive may
also try herbal and botanical “natural†remedies, such as feverfew,
turmeric, colloidal oatmeal, niacinamide and quassia
extract.12,13 In addition, other alternative therapies, such as colloidal
silver, emu oil, laurelwood, oregano oil and vitamin K
have been promoted as possible ways to treat rosacea.14 While
many of the ingredients show promise, there is a paucity of
data regarding the effects of these cosmeceuticals and further
studies are warranted.
Lasers and Light Sources
Both the pulsed dye laser and intense pulsed light treatments
have been found to be effective at reducing the erythema of
rosacea by selectively targeting the red hemoglobin pigment
in blood vessels, thermally coagulating blood, and destroying
the blood vessel walls without damaging the overlying skin.15,16
Lifestyle Modifications
Avoidance of triggers (hot, cold, wind, sun exposure, emotional
issues), dietary changes (spicy foods, alcohol), use of daily sunscreen,
gentle cleansers and proper skin care are also necessary
measures in controlling rosacea.17,18 Concealing cosmetics that
can counteract the redness (such as green-tinted emollients)
are useful adjuncts in improving quality of life and self-esteem
in the management of this chronic condition.
Latest Emerging Trends
Alpha Adrenergic Agonists: Brimonidine and Oxymetazoline
The alpha adrenergic agonists brimonidine tartrate and oxymetazoline
are currently found in eye drops for glaucoma and
a nasal decongestant spray, respectively.19 They have potent
vasoconstrictive capabilities and anti-redness effects.
Topical brimonidine tartrate, 0.33% gel, an alpha 2 agonist,
was approved by the FDA in September 2013, for the treatment
of persistent facial erythema of rosacea. In clinical
studies, a single application of the 0.5% gel reduced erythema
up to 12 hours.20
Oxymetazoline, a potent alpha-1 and partial alpha-2 receptor
agonist has also shown promise for reducing facial erythema.21
A topical form of oxymetazoline is currently being investigated
for the treatment of erythematotelangiectatic rosacea.22